Eikon Therapeutics, Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Eikon Therapeutics presented Phase 1/2 data for three drug candidates at the 2026 ESMO Congress (October 23, 2026): EIK1003 (PARP1 inhibitor, 65–61 participants across monotherapy and combination cohorts), EIK1004 (CNS-penetrant PARP1 inhibitor, 68 participants), and EIK1005 (WRN helicase inhibitor, 11 participants). EIK1003 showed ORRs of 14.3% monotherapy, 20.8% in combination with abiraterone, and 26.4% with paclitaxel; EIK1004 showed 12.1% ORR with minimal hematologic toxicity; EIK1005 showed early safety tolerability and 75% stable disease in monotherapy dose escalation. Additional data from all three programs expected in 2027.
Why this rating
Early-stage oncology data supports pipeline advancement and differentiation; early efficacy signals modest but promising; no transformational results; ordinary clinical-stage disclosure relative to $779.6M asset base.
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.